These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 33276671)

  • 1. Liver Growth Factor "LGF" as a Therapeutic Agent for Alzheimer's Disease.
    Gonzalo-Gobernado R; Perucho J; Vallejo-Muñoz M; Casarejos MJ; Reimers D; Jiménez-Escrig A; Gómez A; Ulzurrun de Asanza GM; Bazán E
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33276671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.
    Zhang W; Zhang W; Li Z; Hao J; Zhang Z; Liu L; Mao N; Miao J; Zhang L
    Pharmacol Biochem Behav; 2012 Jan; 100(3):361-9. PubMed ID: 21993310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.
    Zhu X; Wang S; Yu L; Jin J; Ye X; Liu Y; Xu Y
    Aging Cell; 2017 Oct; 16(5):1073-1082. PubMed ID: 28771976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased tauopathy drives microglia-mediated clearance of beta-amyloid.
    Chen W; Abud EA; Yeung ST; Lakatos A; Nassi T; Wang J; Blum D; Buée L; Poon WW; Blurton-Jones M
    Acta Neuropathol Commun; 2016 Jun; 4(1):63. PubMed ID: 27339073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.
    Rodríguez Cruz Y; Strehaiano M; Rodríguez Obaya T; García Rodríguez JC; Maurice T
    J Alzheimers Dis; 2017; 55(1):231-248. PubMed ID: 27662300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology.
    Rothman SM; Tanis KQ; Gandhi P; Malkov V; Marcus J; Pearson M; Stevens R; Gilliland J; Ware C; Mahadomrongkul V; O'Loughlin E; Zeballos G; Smith R; Howell BJ; Klappenbach J; Kennedy M; Mirescu C
    J Neuroinflammation; 2018 Sep; 15(1):256. PubMed ID: 30189875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse.
    Ontiveros-Torres MÁ; Labra-Barrios ML; Díaz-Cintra S; Aguilar-Vázquez AR; Moreno-Campuzano S; Flores-Rodríguez P; Luna-Herrera C; Mena R; Perry G; Florán-Garduño B; Luna-Muñoz J; Luna-Arias JP
    J Alzheimers Dis; 2016 Mar; 52(1):243-69. PubMed ID: 27031470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.
    Bi Oh S; Suh N; Kim I; Lee JY
    Brain Res; 2015 Feb; 1597():159-67. PubMed ID: 25454795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice.
    Belfiore R; Rodin A; Ferreira E; Velazquez R; Branca C; Caccamo A; Oddo S
    Aging Cell; 2019 Feb; 18(1):e12873. PubMed ID: 30488653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
    Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
    Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of α4 integrins reduces leukocyte-endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer's disease.
    Pietronigro E; Zenaro E; Bianca VD; Dusi S; Terrabuio E; Iannoto G; Slanzi A; Ghasemi S; Nagarajan R; Piacentino G; Tosadori G; Rossi B; Constantin G
    Sci Rep; 2019 Aug; 9(1):12055. PubMed ID: 31427644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.
    Brunner D; Flunkert S; Neddens J; Duller S; Scopes DIC; Treherne JM; Hutter-Paier B
    Neurosci Lett; 2017 Nov; 660():96-102. PubMed ID: 28917978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrogen sulfide slows down progression of experimental Alzheimer's disease by targeting multiple pathophysiological mechanisms.
    Giuliani D; Ottani A; Zaffe D; Galantucci M; Strinati F; Lodi R; Guarini S
    Neurobiol Learn Mem; 2013 Sep; 104():82-91. PubMed ID: 23726868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microglia limit the expansion of β-amyloid plaques in a mouse model of Alzheimer's disease.
    Zhao R; Hu W; Tsai J; Li W; Gan WB
    Mol Neurodegener; 2017 Jun; 12(1):47. PubMed ID: 28606182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micro-RNA-137 Inhibits Tau Hyperphosphorylation in Alzheimer's Disease and Targets the CACNA1C Gene in Transgenic Mice and Human Neuroblastoma SH-SY5Y Cells.
    Jiang Y; Xu B; Chen J; Sui Y; Ren L; Li J; Zhang H; Guo L; Sun X
    Med Sci Monit; 2018 Aug; 24():5635-5644. PubMed ID: 30102687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.